Market Place
Sourcing Support
Actimed`s S-oxprenolol Gets FDA Orphan Drug Status For ALS
04 Sep 2024 //
GLOBENEWSWIRE
Actimed Therapeutics Appoints Martin Walton as Chief Financial Officer
19 Oct 2023 //
GLOBENEWSWIRE
Actimed announces FDA approval of its IND for Phase 2b/3 of S-pindolol benzoate
07 Sep 2023 //
GLOBENEWSWIRE
Actimed closes over-subscribed Series A Financing Round of £5 million
26 Jun 2023 //
GLOBENEWSWIRE
Actimed Therapeutics successfully closes second tranche of £10m seed financing
04 Jan 2023 //
PR NEWSWIRE
Actimed gets US patent for ACM-001 & Canadian patent for ACM-002
14 Oct 2021 //
PHARMABIZ
Actimed Therapeutics Continues to Strengthen Intellectual Property Portfolio
13 Oct 2021 //
PRNEWSWIRE
Actimed Therapeutics Successfully Closed of £2.5m Extended Seed B Funding Round
10 Jun 2021 //
PRNEWSWIRE
Actimed and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol
13 Apr 2021 //
PRNESWIRE
Actimed and Faraday Announce License Agreement for S-oxprenolol
13 Apr 2021 //
PRNESWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.